Cold Plasma in Healthcare Market By Product Type (Devices, Consumables, Services and Software); By Technology (Dielectric Barrier Discharge, Plasma Jet, Radio-Frequency Cold Plasma, Microwave Cold Plasma, Other Cold Plasma Technologies); By Pressure Type (Atmospheric Pressure Cold Plasma, Low-Pressure / Vacuum Cold Plasma); By Application (Wound Healing and Chronic Wound Management, Oncology Applications, Hemostasis and Blood Coagulation, Dentistry and Oral Care, Dermatology, Sterilization and Disinfection, Implant Surface Functionalization, Plasma-Activated Liquids and Hydrogels); By End User (Hospitals, Ambulatory Surgical Centers, Wound Care Centers, Specialty Clinics, Research and Academic Institutes, Home Care Settings); By Region – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032
The global Cold Plasma in Healthcare Market size was estimated at USD 2,873 million in 2025 and is expected to reach USD 6,634 million by 2032, growing at a CAGR of 12.7% from 2025 to 2032. Demand is being propelled by wider clinical adoption of non-thermal plasma modalities for wound care workflows that prioritize microbial control, biofilm disruption, and improved healing outcomes without heat-related tissue damage. North America and Europe remain the primary adoption centers, supported by established hospital procurement channels, while Asia Pacific is gaining momentum as device availability and clinical familiarity expand across large care networks.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
Cold Plasma in Healthcare Market Size 2025
USD 2,873 million
Cold Plasma in Healthcare Market, CAGR
12.7%
Cold Plasma in Healthcare Market Size 2032
USD 6,634 million
Key Market Trends & Insights
The market expands from USD 2,873 million (2025) to USD 6,634 million (2032), reflecting 12.7% CAGR (2025–2032).
North America held 38.90% share (2025), reflecting early commercialization, hospital purchasing power, and broader clinical trial activity.
Europe accounted for 31.20% share (2025), supported by strong med-tech adoption in wound care and structured clinical pathways.
Devices represented 68.40% share (2025), indicating capital equipment leads adoption before recurring streams scale.
Atmospheric Pressure Cold Plasma captured 66.80% share (2025), reflecting operational practicality for point-of-care and bedside use.
Segment Analysis
Cold plasma adoption in healthcare is progressing from specialist use cases into broader clinical workflows where non-thermal surface interaction, controlled delivery, and antimicrobial positioning support treatment standardization. The category remains device-led, with installed base expansion shaping downstream demand for consumables and service-layer integration. Providers increasingly prioritize usability, procedure fit, and treatment reproducibility, which reinforces demand for platforms that can be deployed at the bedside or within outpatient clinical settings.
Application breadth is expanding beyond wound management into adjacent areas such as dentistry, dermatology, and sterilization-linked uses, although utilization remains concentrated where clinical protocols and staff training are easiest to implement. As evidence and clinician familiarity strengthen, adoption is expected to extend into additional procedural environments, supporting higher utilization rates and stronger recurring revenue potential across consumables and software-enabled monitoring.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Devices accounted for the largest share of 68.40% in 2025. Device dominance reflects the need for hospitals and clinics to establish treatment capability through capital equipment before expanding utilization across departments. Procurement decisions favor platforms that fit routine workflows and support consistent dosing and safety controls. Installed-base growth also improves clinician familiarity and protocol adoption, which increases utilization over time. As procedures scale, devices create a foundation for consumables and software services to expand.
By Technology Insights
Plasma Jet accounted for the largest share of 39.60% in 2025. Plasma jet systems align well with clinical practice because they support targeted application in wound beds and localized treatment areas. The technology benefits from portability, ease of deployment, and compatibility with outpatient use. Clinicians also value platforms that enable repeatable application without complex setup. As training and protocol standardization improves, plasma jet adoption remains a primary entry point for many providers.
By Pressure Type Insights
Atmospheric Pressure Cold Plasma accounted for the largest share of 66.80% in 2025. Atmospheric systems lead because they reduce operational complexity and are easier to integrate into standard care environments. Point-of-care delivery supports faster throughput, simpler setup, and fewer facility constraints compared with chamber-based approaches. These systems are also well suited to outpatient and wound care center deployment. The format supports broader utilization once clinical teams gain experience and confidence in protocols.
By Application Insights
Wound Healing and Chronic Wound Management accounted for the largest share of 28.90% in 2025. Wound care leads because it offers a clear clinical pathway for adoption, measurable outcomes, and repeat-treatment workflows that fit outpatient models. Chronic wounds often require ongoing intervention, which supports consistent utilization once devices are deployed. Providers prioritize solutions that strengthen microbial control and healing progression within established wound protocols. As adoption expands, wound care remains the anchor use case that drives broader market penetration.
By End User Insights
Hospitals accounted for the largest share of 41.70% in 2025. Hospitals lead due to centralized procurement, access to multidisciplinary clinical teams, and higher volumes of complex cases that benefit from adjunct wound management tools. These settings also support protocol development, training programs, and evidence-building across departments. Hospital infection prevention priorities reinforce interest in advanced non-thermal modalities. Over time, hospitals also influence downstream adoption as outpatient sites align with hospital-led standards of care.
Cold Plasma in Healthcare Market Drivers
Rising chronic wound burden and clinical demand for adjunct therapies
Growth is supported by the need to improve outcomes in chronic wounds that require repeat interventions and standardized care pathways. Cold plasma solutions align with wound care priorities that emphasize microbial control, biofilm disruption, and tissue-friendly approaches that avoid thermal injury. Health systems also seek tools that can be deployed in outpatient settings to reduce inpatient load and improve throughput. As protocols become more consistent, utilization increases and supports scaling across more care sites.
For instance, Coldplasmatech’s CPT®patch uses an automatic 2-minute treatment cycle, is applied 2 to 3 times per week, and the company states that noticeable and visible progress is often achieved after 6 to 10 treatments over approximately 4 to 5 weeks, reinforcing its fit with repeatable chronic wound care pathways.
Hospital procurement capacity and workflow integration
Hospitals continue to shape market adoption because centralized purchasing enables faster deployment of new technologies across multiple departments. Cold plasma platforms benefit when procurement teams can justify investment through repeat-use economics, standardized protocols, and measurable improvements in clinical processes. Cross-department coordination supports training, credentialing, and consistent operating procedures. Once installed, hospitals often drive wider adoption across affiliated outpatient networks, helping expand utilization and improving device run rates.
For instance, neoplas med’s kINPen® MED is CE-marked as a class IIa medical device and follows a defined treatment protocol with an effective plasma area of about 1 cm², a recommended treatment time of 30 to 60 seconds per cm², and a gas flow of 5.0 l/min, giving hospitals a clearly specified framework for standard operating procedures and staff training.
Shift toward point-of-care modalities and non-thermal treatment formats
Clinical settings increasingly prioritize technologies that can be applied at the bedside with minimal disruption to routine care. Atmospheric pressure systems reinforce this shift by enabling deployment without complex facility requirements. Providers value portable platforms that can be integrated into wound care routines, specialty clinics, and outpatient settings. As confidence in use increases, treatment frequency and site penetration rise. This dynamic reinforces device adoption and creates pull for service and consumable layers.
Expanding clinical applications and protocol maturation
The market benefits from a widening application set that includes dentistry, dermatology, sterilization-related workflows, and implant surface functionalization use cases. As early adoption concentrates in wound care, clinical familiarity creates a pathway for adjacent indications that share similar workflow needs. Protocol maturation improves reproducibility, safety assurance, and staff acceptance. This supports broader departmental adoption within hospitals and specialty clinics. Over time, application expansion strengthens utilization and improves commercialization efficiency.
Cold Plasma in Healthcare Market Challenges
Clinical adoption still depends on consistent evidence, standardized dosing frameworks, and clinician confidence across different care settings. Variability in protocols and differences in device designs can slow broader institutional rollouts, particularly in organizations that require tightly defined clinical pathways. Training requirements and workflow change management add operational friction for new users. Reimbursement clarity can also influence purchasing decisions, especially in outpatient sites where budgets are tightly managed.
For instance, Medtronic’s Pathway Accelerator program demonstrated that without standardized care pathway integration, procedure times at partner hospitals averaged 86 minutes which fell to 58 minutes (a 33% reduction) only after formal pathway standardization was implemented, with referral-to-treatment time compressing from 12–14 weeks down to 2–3 weeks (a 79% reduction).
Cost sensitivity and procurement scrutiny remain barriers in markets where capital allocation competes with other priorities. Providers often require clear operational and clinical justification before scaling deployment across departments or networks. Maintenance, service support, and replacement part availability can influence lifecycle cost perceptions. In newer geographies, limited local service coverage may constrain adoption speed. These factors can slow expansion even when clinical interest is increasing.
Cold Plasma in Healthcare Market Trends and Opportunities
Care delivery is shifting toward outpatient settings, and cold plasma platforms that support efficient point-of-care treatment are positioned to benefit. Ambulatory environments value portability, faster setup, and consistent protocols that can be applied at scale across multiple sites. Opportunities increase when device vendors support training and workflow integration that reduces operational friction. This shift also supports higher utilization as more sites adopt standardized wound care routines.
For instance, terraplasma medical states that its plasma care® device is approximately the size and weight of a telephone receiver, delivers about 120 treatments per battery charge, treats 13 cm² per application, and can be used up to 6 times in one session for a total treatment area of about 73 cm², which directly supports mobile, repeatable wound-care workflows in outpatient settings.
Commercial models are evolving toward bundled offerings that combine devices, consumables, and software-enabled monitoring. As providers seek accountability and traceability, data capture and outcomes tracking become more important to procurement and clinical teams. This creates opportunities for service and software differentiation that improves customer retention and recurring revenue. Vendors that support evidence-building and protocol standardization can accelerate adoption. Over time, integrated offerings can strengthen competitiveness and improve total value realization.
Regional Insights
North America
North America accounted for 38.90% share in 2025, reflecting earlier commercialization and stronger adoption within hospital-led care models. Health systems in the region tend to adopt technologies that integrate into established wound care pathways and infection prevention priorities. Provider networks also support protocol standardization and multi-site deployment once early results are validated. Academic and clinical ecosystems reinforce evidence generation, which helps scale utilization across broader clinical settings.
Europe
Europe held 31.20% share in 2025, supported by strong med-tech adoption and clinical pathway discipline in wound care and specialty clinics. The region benefits from mature hospital infrastructure and a focus on standardized protocols that improve reproducibility and clinician confidence. Adoption is often influenced by structured procurement frameworks and emphasis on demonstrable outcomes. As utilization grows, cross-border diffusion can accelerate as best practices spread across key markets.
Asia Pacific
Asia Pacific reached 21.00% share in 2025, reflecting expanding hospital capacity and growing interest in advanced wound management technologies. Large patient volumes and increasing modernization of clinical infrastructure support adoption potential, especially as device availability improves. Providers are also scaling outpatient models to manage chronic care demand more efficiently. As training, protocols, and procurement familiarity expand, adoption is positioned to strengthen across major healthcare hubs.
Latin America
Latin America represented 5.70% share in 2025, with adoption typically centered in larger private hospital systems and specialty clinics that can support investment and training. Procurement cycles may be slower due to budget constraints and uneven access to advanced care infrastructure. Even so, rising chronic disease burden supports demand for improved wound care approaches. Targeted deployments can expand as clinical champions and reference sites demonstrate repeatable workflows.
Middle East & Africa
The Middle East and Africa accounted for 3.20% share in 2025, driven by selective uptake in specialty care centers and hospitals with modernization initiatives. Adoption often begins through pilot programs and reference deployments that prove workflow fit and clinical value. Concentrated demand in higher-investment markets can support early scaling for suppliers with service coverage. Over time, broader penetration depends on procurement pathways and local clinical training capacity.
Competitive Landscape
Competition is shaped by differentiation in device usability, protocol support, safety controls, and the ability to fit into wound care and outpatient workflows. Vendors compete on clinical positioning, deployment simplicity, and service readiness, with increasing emphasis on integrated offerings that improve adoption and retention. Partnerships with hospitals, distributors, and clinical stakeholders influence market access. As the installed base grows, recurring layers such as consumables and software increasingly influence customer stickiness and lifecycle value.
terraplasma medical GmbH focuses on advancing cold plasma capabilities that align with clinical needs in disinfection and related healthcare workflows. The company’s positioning benefits when solutions demonstrate repeatability, operational simplicity, and compatibility with routine clinical procedures. Product performance and service support can influence adoption speed, especially when health systems seek scalable approaches across multiple sites. Differentiation is strengthened through clinical validation, training support, and alignment with infection control priorities in care environments.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In February 2025, Royal Wound-X, a division of Royal Biologics, entered a strategic partnership with Coldplasmatech GmbH to expand the treatment of complex and chronic wounds worldwide. The partnership centers on Coldplasmatech’s Cold Atmospheric Plasma platform, including the CPT cube and CPT patch, which the companies said is designed to support rapid and safe wound therapy, especially for difficult wounds complicated by infection.
In April 2025, Viromed Medical AG signed an exclusive distribution agreement with Korea-based UMECO Group for the commercialization of its cold plasma medical devices ViroCAP and PulmoPlas in ten Asian countries. Viromed said the agreement gives UMECO exclusive marketing and distribution rights for these devices in dermatological and pneumological applications, marking a significant regional partnership in cold plasma-based healthcare.
In June 2025, Neoplas officially launched its Argon Cold Plasma Jet kINPen MED in Oman during an event in Muscat attended by more than 150 healthcare professionals. The launch introduced a non-invasive cold plasma therapy positioned for wound care, tissue regeneration, and infection management, reflecting continued product expansion in healthcare applications.
In June 2025, hyped science GmbH launched PHLAS, a cold plasma device for medical aesthetic applications and home-use skincare. According to market coverage, the handheld device is based on patented SMD cold plasma technology and was presented as a new commercial step for cold plasma in skin-focused healthcare and aesthetic treatment.
Report Scope
Report Attribute
Details
Market size value in 2025
USD 2,873 million
Revenue forecast in 2032
USD 6,634 million
Growth rate (CAGR)
12.7% (2025–2032)
Base year
2025
Forecast period
2026-2032
Quantitative units
USD million
Segments covered
By Product Type Outlook: Devices, Consumables, Services and Software; By Technology Outlook: Dielectric Barrier Discharge, Plasma Jet, Radio-Frequency Cold Plasma, Microwave Cold Plasma, Other Cold Plasma Technologies; By Pressure Type Outlook: Atmospheric Pressure Cold Plasma, Low-Pressure / Vacuum Cold Plasma; By Application Outlook: Wound Healing and Chronic Wound Management, Oncology Applications, Hemostasis and Blood Coagulation, Dentistry and Oral Care, Dermatology, Sterilization and Disinfection, Implant Surface Functionalization, Plasma-Activated Liquids and Hydrogels; By End User Outlook: Hospitals, Ambulatory Surgical Centers, Wound Care Centers, Specialty Clinics, Research and Academic Institutes, Home Care Settings
Regional scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Key companies profiled
terraplasma medical GmbH; neoplas med GmbH; Plasmacure B.V.; Coldplasmatech GmbH; Adtec Healthcare / Adtec Plasma Technology; Apyx Medical Corporation; Erbe Elektromedizin GmbH; Plasmology4; Plasmatreat GmbH; Viromed Medical GmbH; relyon plasma GmbH; TDK Electronics AG
No.of Pages
345
Segmentation
By Product Type
Devices
Consumables
Services and Software
By Technology
Dielectric Barrier Discharge
Plasma Jet
Radio-Frequency Cold Plasma
Microwave Cold Plasma
Other Cold Plasma Technologies
By Pressure Type
Atmospheric Pressure Cold Plasma
Low-Pressure / Vacuum Cold Plasma
By Application
Wound Healing and Chronic Wound Management
Oncology Applications
Hemostasis and Blood Coagulation
Dentistry and Oral Care
Dermatology
Sterilization and Disinfection
Implant Surface Functionalization
Plasma-Activated Liquids and Hydrogels
By End User
Hospitals
Ambulatory Surgical Centers
Wound Care Centers
Specialty Clinics
Research and Academic Institutes
Home Care Settings
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
1. Introduction
1.1 Report Description
1.2 Purpose of the Report
1.3 USP & Key Offerings
1.4 Key Benefits for Stakeholders
1.5 Target Audience
1.6 Report Scope
1.7 Regional Scope 2. Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology 3. Executive Summary 4. Introduction
4.1 Overview
4.2 Key Industry Trends 5. Global Cold Plasma in Healthcare Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast 6. Market Breakup by Product Type
6.1 Devices
6.1.1 Market Trends
6.1.2 Market Forecast
6.1.3 Revenue Share
6.1.4 Revenue Growth Opportunity
6.2 Consumables
6.2.1 Market Trends
6.2.2 Market Forecast
6.2.3 Revenue Share
6.2.4 Revenue Growth Opportunity
6.3 Services and Software
6.3.1 Market Trends
6.3.2 Market Forecast
6.3.3 Revenue Share
6.3.4 Revenue Growth Opportunity 7. Market Breakup by Technology
7.1 Dielectric Barrier Discharge
7.1.1 Market Trends
7.1.2 Market Forecast
7.1.3 Revenue Share
7.1.4 Revenue Growth Opportunity
7.2 Plasma Jet
7.2.1 Market Trends
7.2.2 Market Forecast
7.2.3 Revenue Share
7.2.4 Revenue Growth Opportunity
7.3 Radio-Frequency Cold Plasma
7.3.1 Market Trends
7.3.2 Market Forecast
7.3.3 Revenue Share
7.3.4 Revenue Growth Opportunity
7.4 Microwave Cold Plasma
7.4.1 Market Trends
7.4.2 Market Forecast
7.4.3 Revenue Share
7.4.4 Revenue Growth Opportunity
7.5 Other Cold Plasma Technologies
7.5.1 Market Trends
7.5.2 Market Forecast
7.5.3 Revenue Share
7.5.4 Revenue Growth Opportunity 8. Market Breakup by Pressure Type
8.1 Atmospheric Pressure Cold Plasma
8.1.1 Market Trends
8.1.2 Market Forecast
8.1.3 Revenue Share
8.1.4 Revenue Growth Opportunity
8.2 Low-Pressure / Vacuum Cold Plasma
8.2.1 Market Trends
8.2.2 Market Forecast
8.2.3 Revenue Share
8.2.4 Revenue Growth Opportunity 9. Market Breakup by Application
9.1 Wound Healing and Chronic Wound Management
9.1.1 Market Trends
9.1.2 Market Forecast
9.1.3 Revenue Share
9.1.4 Revenue Growth Opportunity
9.2 Oncology Applications
9.2.1 Market Trends
9.2.2 Market Forecast
9.2.3 Revenue Share
9.2.4 Revenue Growth Opportunity
9.3 Hemostasis and Blood Coagulation
9.3.1 Market Trends
9.3.2 Market Forecast
9.3.3 Revenue Share
9.3.4 Revenue Growth Opportunity
9.4 Dentistry and Oral Care
9.4.1 Market Trends
9.4.2 Market Forecast
9.4.3 Revenue Share
9.4.4 Revenue Growth Opportunity
9.5 Dermatology
9.5.1 Market Trends
9.5.2 Market Forecast
9.5.3 Revenue Share
9.5.4 Revenue Growth Opportunity
9.6 Sterilization and Disinfection
9.6.1 Market Trends
9.6.2 Market Forecast
9.6.3 Revenue Share
9.6.4 Revenue Growth Opportunity
9.7 Implant Surface Functionalization
9.7.1 Market Trends
9.7.2 Market Forecast
9.7.3 Revenue Share
9.7.4 Revenue Growth Opportunity
9.8 Plasma-Activated Liquids and Hydrogels
9.8.1 Market Trends
9.8.2 Market Forecast
9.8.3 Revenue Share
9.8.4 Revenue Growth Opportunity 10. Market Breakup by End User
10.1 Hospitals
10.1.1 Market Trends
10.1.2 Market Forecast
10.1.3 Revenue Share
10.1.4 Revenue Growth Opportunity
10.2 Ambulatory Surgical Centers
10.2.1 Market Trends
10.2.2 Market Forecast
10.2.3 Revenue Share
10.2.4 Revenue Growth Opportunity
10.3 Wound Care Centers
10.3.1 Market Trends
10.3.2 Market Forecast
10.3.3 Revenue Share
10.3.4 Revenue Growth Opportunity
10.4 Specialty Clinics
10.4.1 Market Trends
10.4.2 Market Forecast
10.4.3 Revenue Share
10.4.4 Revenue Growth Opportunity
10.5 Research and Academic Institutes
10.5.1 Market Trends
10.5.2 Market Forecast
10.5.3 Revenue Share
10.5.4 Revenue Growth Opportunity
10.6 Home Care Settings
10.6.1 Market Trends
10.6.2 Market Forecast
10.6.3 Revenue Share
10.6.4 Revenue Growth Opportunity 11. Market Breakup by Region
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia-Pacific
11.2.1 China
11.2.2 Japan
11.2.3 India
11.2.4 South Korea
11.2.5 Australia
11.2.6 Rest of Asia-Pacific
11.3 Europe
11.3.1 Germany
11.3.2 France
11.3.3 United Kingdom
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Latin America
11.4.1 Brazil
11.4.2 Mexico
11.4.3 Rest of Latin America
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast 12. SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats 13. Value Chain Analysis 14. Porter’s Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes 15. Price Analysis 16. Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 terraplasma medical GmbH
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 neoplas med GmbH
16.3.3 Plasmacure B.V.
16.3.4 Coldplasmatech GmbH
16.3.5 Adtec Healthcare / Adtec Plasma Technology
16.3.6 Apyx Medical Corporation
16.3.7 Erbe Elektromedizin GmbH
16.3.8 Plasmology4
16.3.9 Plasmatreat GmbH
16.3.10 Viromed Medical GmbH
16.3.11 relyon plasma GmbH
16.3.12 TDK Electronics AG 17. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the market size and forecast for the Cold Plasma in Healthcare Market?
The Cold Plasma in Healthcare Market was valued at USD 2,873 million in 2025. The market is projected to reach USD 6,634 million by 2032.
What is the CAGR for the Cold Plasma in Healthcare Market?
The market is expected to grow at a 12.7% CAGR. The forecast period is 2025–2032.
Which segment holds the largest share in the Cold Plasma in Healthcare Market?
Devices lead the market with 68.40% share in 2025. Device-led adoption reflects installed-base expansion and workflow integration.
What factors are driving growth in the Cold Plasma in Healthcare Market?
Growth is driven by chronic wound demand, infection control priorities, and point-of-care adoption. Protocol maturation and expanding applications also support wider utilization.
Who are the leading companies in the Cold Plasma in Healthcare Market?
Key companies include terraplasma medical GmbH, neoplas med GmbH, Plasmacure B.V., Apyx Medical Corporation, and Erbe Elektromedizin GmbH, among others. Competition centers on device usability, clinical fit, and service readiness.
Which region leads the Cold Plasma in Healthcare Market?
North America leads with 38.90% share in 2025. Strong hospital procurement capacity and early commercialization support regional leadership.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The global Cloud Based Solutions For Drug Discovery Development And Manufacturing Market size was estimated at USD 2479 million in 2025 and is expected to reach USD 3442 million by 2032, growing at a CAGR of 4.8% from 2025 to 2032.
The global Clinical Trial Investigative Site Network Market size was estimated at USD 9379 million in 2025 and is expected to reach USD 14826 million by 2032, growing at a CAGR of 6.76% from 2025 to 2032.
The global Clinical Risk Grouping Solutions Market size was estimated at USD 823.92 million in 2025 and is expected to reach USD 1,748 million by 2032, growing at a CAGR of 11.34% from 2025 to 2032.
The global Clinical Perinatal Software Market size was estimated at USD 363.05 million in 2025 and is expected to reach USD 723 million by 2032, growing at a CAGR of 10.35% from 2025 to 2032.
The global Clinical Trial Patient Recruitment Services Market size was estimated at USD 1039 million in 2025 and is expected to reach USD 1733 million by 2032, growing at a CAGR of 7.58% from 2025 to 2032.
The global Clinical Trial Supply Market size was estimated at USD 5,249 million in 2025 and is expected to reach USD 9,412 million by 2032, growing at a CAGR of 8.7% from 2025 to 2032.
The global Clinical Oncology NGS Market size was estimated at USD 8206 million in 2025 and is expected to reach USD 20914 million by 2032, growing at a CAGR of 14.3% from 2025 to 2032.
The global Clinical EHR Market size was estimated at USD 42622 million in 2025 and is expected to reach USD 62331 million by 2032, growing at a CAGR of 5.58% from 2025 to 2032.
The global Clear Aligners Market size was estimated at USD 5,136 million in 2025 and is expected to reach USD 8,498 million by 2032, growing at a CAGR of 7.46% from 2025 to 2032.
The global CircRNA Synthesis Market size was estimated at USD 189.75 million in 2025 and is expected to reach USD 527 million by 2032, growing at a CAGR of 15.7% from 2025 to 2032,
The global Circular Dichroism Spectrometers Market size was estimated at USD 38.27 million in 2025 and is expected to reach USD 58 million by 2032, growing at a CAGR of 6.1% from 2025 to 2032.
The global Complex Injectables Market size was estimated at USD 26,141 million in 2025 and is expected to reach USD 46,572 million by 2032, growing at a CAGR of 8.6% from 2025 to 2032.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
